Annual Cash & Cash Equivalents
$56.57 M
+$41.52 M+275.93%
December 31, 2023
Summary
- As of February 8, 2025, SABS annual cash & cash equivalents is $56.57 million, with the most recent change of +$41.52 million (+275.93%) on December 31, 2023.
- During the last 3 years, SABS annual cash & cash equivalents has risen by +$43.96 million (+348.57%).
- SABS annual cash & cash equivalents is now at all-time high.
Performance
SABS Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$9.17 M
-$8.07 M-46.81%
September 30, 2024
Summary
- As of February 8, 2025, SABS quarterly cash and cash equivalents is $9.17 million, with the most recent change of -$8.07 million (-46.81%) on September 30, 2024.
- Over the past year, SABS quarterly cash and cash equivalents has increased by +$6.75 million (+278.12%).
- SABS quarterly cash and cash equivalents is now -83.79% below its all-time high of $56.57 million, reached on December 31, 2023.
Performance
SABS Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
SABS Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +275.9% | +278.1% |
| 3 y3 years | +348.6% | +10.1% |
| 5 y5 years | +791.4% | +10.1% |
SABS Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +275.9% | -83.8% | +278.1% |
| 5 y | 5-year | at high | +791.4% | -83.8% | +1273.1% |
| alltime | all time | at high | +791.4% | -83.8% | +1273.1% |
SAB Biotherapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $9.17 M(-46.8%) |
| Jun 2024 | - | $17.24 M(+22.9%) |
| Mar 2024 | - | $14.03 M(-75.2%) |
| Dec 2023 | $56.57 M(+275.9%) | $56.57 M(+2232.1%) |
| Sep 2023 | - | $2.43 M(-68.8%) |
| Jun 2023 | - | $7.77 M(-40.5%) |
| Mar 2023 | - | $13.06 M(-13.2%) |
| Dec 2022 | $15.05 M | $15.05 M(+80.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $8.33 M(-49.9%) |
| Jun 2022 | - | $16.62 M(-25.8%) |
| Mar 2022 | - | $22.41 M(-32.5%) |
| Dec 2021 | $33.21 M(+163.3%) | $33.21 M(+4871.8%) |
| Sep 2021 | - | $667.90 K(-93.5%) |
| Jun 2021 | - | $10.23 M(-18.9%) |
| Dec 2020 | $12.61 M(+98.7%) | $12.61 M |
| Dec 2019 | $6.35 M | - |
FAQ
- What is SAB Biotherapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for SAB Biotherapeutics?
- What is SAB Biotherapeutics annual cash & cash equivalents year-on-year change?
- What is SAB Biotherapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for SAB Biotherapeutics?
- What is SAB Biotherapeutics quarterly cash and cash equivalents year-on-year change?
What is SAB Biotherapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of SABS is $56.57 M
What is the all time high annual cash & cash equivalents for SAB Biotherapeutics?
SAB Biotherapeutics all-time high annual cash & cash equivalents is $56.57 M
What is SAB Biotherapeutics annual cash & cash equivalents year-on-year change?
Over the past year, SABS annual cash & cash equivalents has changed by +$41.52 M (+275.93%)
What is SAB Biotherapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of SABS is $9.17 M
What is the all time high quarterly cash and cash equivalents for SAB Biotherapeutics?
SAB Biotherapeutics all-time high quarterly cash and cash equivalents is $56.57 M
What is SAB Biotherapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, SABS quarterly cash and cash equivalents has changed by +$6.75 M (+278.12%)